Seven-year-old gene therapy startup Lacerta Therapeutics has folded and sold its assets, a board member confirmed to Endpoints News.
The University of Florida spinout, based …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
After some halting starts, false dawns and fragile rallies, the biotech market may finally be back. No, really. In the last several months, several important
CHICAGO — The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved progression-free survival (PFS) versus chemotherapy in previously treated metastatic hormone receptor-positive (HR+)/HER2-low/ultralow breast
As the Hatch-Waxman Act approaches its 40th anniversary, it’s time to critically examine its legacy and what it actually gave us: the highest drug prices in